AVI BioPharma, Inc. Provides Update On Influenza Drug Development Program

PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 21, 2005--AVI BioPharma, Inc. (Nasdaq:AVII), today provided an update on its NEUGENE(R) antisense drug development program targeting the Influenza A (flu) virus. AVI has targeted genetic regions of the virus that are highly conserved between six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in man (H5N1, H7N7 and H9N2).

Back to news